Orchestra BioMed Holdings (OBIO) Short-term Investments (2022 - 2026)

Orchestra BioMed Holdings (OBIO) has reported Short-term Investments for 5 consecutive years, with $66.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Short-term Investments rose 109.39% year-over-year to $66.0 million; the TTM figure through Mar 2026 stood at $66.0 million (up 109.39% YoY), while the FY2025 annual figure was $71.8 million, up 61.21% from the prior year.
• Short-term Investments declined to $66.0 million in Q1 2026 per OBIO's latest filing, from $71.8 million in the prior quarter.
• Across five years, Short-term Investments topped out at $108.4 million in Q1 2023 and bottomed at $23000.0 in Q1 2024.
• Historically, Short-term Investments has averaged $52.3 million across 5 years, with a median of $53.8 million in 2025.
• Annual changes were most pronounced in 2024 — Short-term Investments plunged 99.98% — and 2025, when it surged 137013.04%.
• Orchestra BioMed Holdings' Short-term Investments stood at $86000.0 in 2022, then surged by 66141.86% to $57.0 million in 2023, then fell by 21.8% to $44.6 million in 2024, then soared by 61.21% to $71.8 million in 2025, then retreated by 8.06% to $66.0 million in 2026.
• Business Quant data shows OBIO's Short-term Investments at $66.0 million in Q1 2026, $71.8 million in Q4 2025, and $53.8 million in Q3 2025.